You are here

BMC medical genomics DOI:10.1186/1755-8794-3-8

Molecular sampling of prostate cancer: a dilemma for predicting disease progression.

Publication TypeJournal Article
Year of Publication2010
AuthorsSboner, A, Demichelis, F, Calza, S, Pawitan, Y, Setlur, SR, Hoshida, Y, Perner, S, Adami, HO, Fall, K, Mucci, LA, Kantoff, PW, Stampfer, M, Andersson, SO, Varenhorst, E, Johansson, JE, Gerstein, MB, Golub, TR, Rubin, MA, Andrén, O
JournalBMC medical genomics
Volume3
Pages8
Date Published2010/03/16
Abstract

Current prostate cancer prognostic models are based on pre-treatment prostate specific antigen (PSA) levels, biopsy Gleason score, and clinical staging but in practice are inadequate to accurately predict disease progression. Hence, we sought to develop a molecular panel for prostate cancer progression by reasoning that molecular profiles might further improve current clinical models.

URLhttp://www.biomedcentral.com/1755-8794/3/8
DOI10.1186/1755-8794-3-8
Pubmed

http://www.ncbi.nlm.nih.gov/pubmed/20233430?dopt=Abstract